However, therapy resistance to TKIs leads to loss of molecular remission in about 25% of CML patients being partially due to BCR::ABL1 kinase mutations, while for the remaining cases, various other mechanisms are discussed. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.